Leslie Kingslow, MD
Pulmonary Disease · Washington, DCNPI 1568417228
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 273 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by GSK at 26.5% of the total.
Across 273 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Bayer$865
- Mallinckrodt Hospital Products Inc.$845
- AstraZeneca$721
- Actelion Pharmaceuticals US, Inc.$586
- Boehringer Ingelheim$296
- plus $1K from 16 others
What the payments were for
- Consulting fees$2003%
- Food & beverage$5,73096%
- Education$681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 82 | $1,590 |
| Bayer | 25 | $865 |
| Mallinckrodt Hospital Products Inc. | 40 | $845 |
| AstraZeneca | 35 | $721 |
| Actelion Pharmaceuticals US, Inc. | 23 | $586 |
| Boehringer Ingelheim | 15 | $296 |
| United Therapeutics Corporation | 9 | $201 |
| Mallinckrodt Enterprises LLC | 10 | $171 |
| Regeneron Healthcare Solutions, Inc. | 6 | $137 |
| Sanofi | 5 | $104 |
| Advanced Respiratory, Inc | 4 | $94 |
| Genentech USA, Inc. | 3 | $59 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Sunovion Pharmaceuticals Inc. | 3 | $55 |
| Mylan Specialty L.p. | 3 | $46 |
| Gilead | 2 | $45 |
| Novartis | 2 | $29 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Grifols USA, LLC | 1 | $24 |
| Watermark Medical, Inc. | 1 | $19 |
| Amgen | 1 | $16 |
| Integra Lifesciences Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$200
How this compares
$5,998 in reported general payments places this provider in the 80th percentile of 56 pulmonary disease providers in District of Columbia.
See all pulmonary disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 104 | $2,257,839 |
| OpsumitMacitentan | 124 | $1,604,120 |
| AdempasRiociguat | 123 | $1,582,976 |
| Orenitram ErTreprostinil Diolamine | 69 | $1,122,923 |
| OfevNintedanib Esylate | 32 | $402,169 |
| Ambrisentan | 98 | $394,975 |
| Tyvaso DpiTreprostinil | 15 | $343,093 |
| LetairisAmbrisentan | 28 | $336,500 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 284 | $228,269 |
| Tadalafil | 155 | $226,493 |
| XolairOmalizumab | 21 | $75,385 |
| NucalaMepolizumab | 15 | $63,753 |
| Spiriva RespimatTiotropium Bromide | 75 | $49,222 |
| Breo ElliptaFluticasone/Vilanterol | 94 | $46,990 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 68 | $38,684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $586 | $3,861,959228 claims |
| BayerAdempas | $865 | $1,582,976123 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $296 | $465,272135 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,590 | $405,035533 claims |
| GileadLetairis | $45 | $336,50028 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $721 | $41,94194 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 56 pulmonary disease providers in District of Columbia.
Other pulmonary disease in Washington
- Andrew ShorrWashington$349K
- Eric AndersonWashington$215K
- Anne OdonnellWashington$61K
- Andrew LernerWashington$19K
- Guillermo GutierrezWashington$14K
- Khalil DiabWashington$10K
- Lorenzo LeysWashington$9K
- Rebecca KrochmalWashington$9K
- Steven LernerWashington$6K
- Karen FaganWashington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.